Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell transplantation (HCT). We describe the results of 122 patients reported to the National Marrow Donor Program between 1990 and 2005, who received a second unrelated donor HCT after failing to achieve an absolute neutrophil count of ≥500/μL without recurrent disease. Patients were transplanted for leukemia (n = 83), myelodysplastic disorders (n = 16), severe aplastic anemia (n = 20), and other diseases (n = 3). The median age was 29 years. Twenty-four patients received second grafts from a different unrelated donor. Among 98 patients who received a second graft from the same donor, 28 received products that were previously collected and cryopreser...
Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone ...
International audienceGraft failure remains a severe complication of hematopoietic stem cell transpl...
AbstractThe survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hem...
Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell tra...
The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoiet...
A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies ...
Purpose To evaluate the role of a second allogeneic hematopoietic stem-cell transplantation (HSCT2) ...
A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individu...
AbstractGraft failure is a significant complication following allogeneic hematopoietic cell transpla...
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162...
AbstractA second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for ...
We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 pa-tients who received transpla...
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162...
AbstractThe long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has ...
Relapse of acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge. Despite the con...
Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone ...
International audienceGraft failure remains a severe complication of hematopoietic stem cell transpl...
AbstractThe survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hem...
Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell tra...
The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoiet...
A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies ...
Purpose To evaluate the role of a second allogeneic hematopoietic stem-cell transplantation (HSCT2) ...
A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individu...
AbstractGraft failure is a significant complication following allogeneic hematopoietic cell transpla...
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162...
AbstractA second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for ...
We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 pa-tients who received transpla...
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162...
AbstractThe long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has ...
Relapse of acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge. Despite the con...
Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone ...
International audienceGraft failure remains a severe complication of hematopoietic stem cell transpl...
AbstractThe survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hem...